Sygnature Discovery has recruited four new senior members to boost its DMPK (drug metabolism and pharmacokinetics) capabilities. Dr Stuart Best, Dr Hayley Butler, Dr Daniel Weston and Dr Bodo Spöri have all joined the senior management team of the company’s DMPK department.
Dr Stuart Best joins as associate director of DMPK and will manage and supervise the growth of the Alderley Park-based part of the DMPK team, and brings more than 25 years’ experience in the pharmaceutical industry, working in regulatory bioanalysis and drug discovery.
Dr Hayley Butler joins the company as a principal scientist. In her previous role at RedX Pharma, she worked on oncology and infection projects, and brings significant project management and PK/PD expertise to the team.
Dr Daniel Weston has been recruited as an associate director, providing significant analytical, mass spectrometry and biotransformation expertise gained at various biotech and large pharma companies.
Finally, Dr Bodo Spöri has joined the company as senior director of business development, having spent 15 years in various business development roles, both European and global, recently at Cyprotex and Domainex.
Director of DMPK Dr Tim Schultz-Utermoehl commented: “I am very pleased with how the DMPK department is growing in Nottingham and Alderley Park. We have a great mix of pharma industry veterans and up-and-coming scientists, all highly-qualified and from a variety of backgrounds. Stuart, Hayley, Daniel and Bodo add considerable experience and expertise, further enriching the senior management team within Sygnature’s DMPK Department.”
